| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 5940- | Cela, | Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway |
| - | in-vivo, | Pca, | PC3 |
| 5941- | Cela, | Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 5948- | Cela, | Recent Trends in anti-tumor mechanisms and molecular targets of celastrol |
| 5949- | Cela, | Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor |
| - | in-vitro, | BC, | MCF7 |
| - | in-vitro, | Melanoma, | KM3/BTZ |
| 6652- | Cen, | AA-PMe, a novel asiatic acid derivative, induces apoptosis and suppresses proliferation, migration, and invasion of gastric cancer cells |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | HGC27 |
| 6642- | Cen, | Asiaticoside inhibits breast cancer progression and tumor angiogenesis via YAP1/VEGFA signal pathway |
| - | vitro+vivo, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 6006- | CGA, | Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF-κB signaling pathway |
| - | in-vitro, | BC, | NA |
| 6009- | CGA, | Chlorogenic Acid: An In-Depth Review of Its Effectiveness in Cancer Treatment |
| - | Review, | Var, | NA |
| 6010- | CGA, | The Biological Activity Mechanism of Chlorogenic Acid and Its Applications in Food Industry: A Review |
| - | Review, | Nor, | NA |
| 6014- | CGA, | Exploring the Pharmacological Potential of Chlorogenic acid as an Anti-Cancer Agent and a Call for Advance Research |
| - | Review, | Var, | NA |
| 6012- | CGA, | Chlorogenic Acid as a Potential Therapeutic Agent for Cholangiocarcinoma |
| - | in-vitro, | CCA, | HCC9810 |
| 6030- | CGA, | Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF‑κB signaling pathway |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-453 | - | in-vitro, | Nor, | MCF10 |
| 1106- | CGA, | Chlorogenic Acid Inhibits Epithelial-Mesenchymal Transition and Invasion of Breast Cancer by Down-Regulating LRP6 |
| - | vitro+vivo, | BC, | MCF7 |
| 7177- | CHA, | Chaetocin inhibits the progression of neuroblastoma by targeting JAK2/STAT3 signaling pathway in SH-SY5Y cells |
| - | NA, | neuroblastoma, | SH-SY5Y |
| 7180- | CHA, | Chaetocin: A review of its anticancer potentials and mechanisms |
| - | Review, | Var, | NA |
| 7181- | CHA, | Chaetocin induces cell cycle arrest and apoptosis by regulating the ROS-mediated ASK-1/JNK signaling pathways |
| 4489- | Chit, | SeNPs, | Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy |
| - | in-vitro, | GBM, | U87MG |
| 6073- | CHL, | GEM, | Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis |
| - | in-vitro, | PC, | NA |
| 6132- | CHr, | MET, | Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression |
| - | in-vitro, | BC, | T47D |
| 6131- | CHr, | Bor, | Z, | Fabrication of phenyl boronic acid modified pH-responsive zinc oxide nanoparticles as targeted delivery of chrysin on human A549 cells |
| - | in-vitro, | Lung, | A549 |
| 6127- | CHr, | Chrysin Inhibits Tumor Promoter-Induced MMP-9 Expression by Blocking AP-1 via Suppression of ERK and JNK Pathways in Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 2590- | CHr, | Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 2786- | CHr, | Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives |
| - | Review, | Var, | NA |
| 2787- | CHr, | Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics |
| - | Analysis, | Var, | MCF7 |
| 3258- | CHr, | PBG, | Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of TET1 Expression in Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 1274- | Cin, | Cinnamon bark extract suppresses metastatic dissemination of cancer cells through inhibition of glycolytic metabolism |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 6161- | Cin, | Cinnamon bark extract suppresses metastatic dissemination of cancer cells through inhibition of glycolytic metabolism |
| - | in-vivo, | BC, | MDA-MB-231 |
| 6164- | Cin, | Advances in pharmacological effects and mechanism of action of cinnamaldehyde |
| - | Review, | Var, | NA | - | Review, | PSA, | NA |
| 6142- | Cin, | Cinnamaldehyde affects the biological behavior of human colorectal cancer cells and induces apoptosis via inhibition of the PI3K/Akt signaling pathway |
| - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | HCT116 |
| 6167- | Cin, | Cinnamaldehydes in Cancer Chemotherapy |
| - | Review, | Var, | NA |
| 6140- | Cin, | HCAs, | Cinnamaldehyde: Pharmacokinetics, anticancer properties and therapeutic potential (Review) |
| - | Review, | Var, | NA |
| 6316- | Cro, | Crocin suppresses prostate cancer progression via TLR4/NF-κB and NLRP3 pathway inhibition |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 |
| 6314- | Cro, | Crocin promotes ferroptosis in gastric cancer via the Nrf2/GGTLC2 pathway |
| - | in-vitro, | GC, | NA |
| 6301- | Cro, | Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways |
| - | vitro+vivo, | Colon, | HT29 | - | in-vitro, | Colon, | Caco-2 |
| 6523- | CRV, | Anticancer effects of Carvone in myeloma cells is mediated through the inhibition of p38 MAPK signalling pathway, apoptosis induction and inhibition of cell invasion |
| - | NA, | Melanoma, | NA |
| 7411- | CS, | Long Term Exposure to Polyphenols of Artichoke (Cynara scolymus L.) Exerts Induction of Senescence Driven Growth Arrest in the MDA-MB231 Human Breast Cancer Cell Line |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HCT116 |
| 7410- | CS, | Artichoke polyphenols induce apoptosis and decrease the invasive potential of the human breast cancer cell line MDA-MB231 |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6182- | Cu, | Role of cuproptosis in digestive system tumors (Review) |
| - | Review, | Var, | NA |
| 4656- | CUR, | EGCG, | Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 4709- | CUR, | Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways |
| - | Review, | Var, | NA |
| 4710- | CUR, | Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 2974- | CUR, | Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | SW-620 | - | in-vivo, | NA, | NA |
| 476- | CUR, | The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer |
| - | in-vitro, | PC, | PATU-8988 | - | in-vitro, | PC, | PANC1 |
| 467- | CUR, | Curcumin inhibits liver cancer by inhibiting DAMP molecule HSP70 and TLR4 signaling |
| - | in-vitro, | Liver, | HepG2 |
| 464- | CUR, | Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vitro, | Thyroid, | TPC-1 |
| 461- | CUR, | Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 460- | CUR, | Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | TCCSUP | - | in-vitro, | Bladder, | J82 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 152- | CUR, | Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer |
| - | in-vivo, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:324 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid